Literature DB >> 16709940

Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice.

Tina Raj1, Peter Kanellakis, Giovanna Pomilio, Garry Jennings, Alex Bobik, Alex Agrotis.   

Abstract

OBJECTIVE: To determine the significance of fibroblast growth factor receptor (FGFR) expression for the development of atherosclerotic lesions in apoE-deficient (apoE-/-) mice. METHODS AND
RESULTS: ApoE-/- mice fed a high-fat diet were administered the FGFR tyrosine kinase inhibitor SU5402 (25 mg/kg/d sc), which inhibited neointima growth by 85%. We measured its effects on lesion size at the aortic sinus, macrophage and smooth muscle cell (SMC) accumulation, the expression of monocyte chemotactic and retention factors, as well as its effects on FGFR expression/phosphorylation. FGFR tyrosine kinase inhibition reduced phosphorylated FGFRs in lesions by 90%, associated with a 65% reduction in lesion size measured using Oil Red O. Macrophages and SMCs within lesions were reduced by 58% and 78%, respectively. Monocyte chemotactic protein-1 (MCP-1) expression was also reduced, as was the expression of hyaluronan synthase, cyclooxygenase-2, CD36, and endothelial monocyte-activating polypeptide-II. Although 3 FGFR types were expressed in lesions, the effects of SU5402 could be attributed largely to inhibition of FGFR-1 phosphorylation.
CONCLUSIONS: Atherosclerotic lesions in apoE-/- mice express multiple FGFRs and an active FGF:FGFR-1 signaling system that promotes atherosclerosis development via increased SMC proliferation, and by augmenting macrophage accumulation via increased expression of MCP-1 and factors promoting macrophage retention in lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709940     DOI: 10.1161/01.ATV.0000227689.41288.5e

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor.

Authors:  Peter Kanellakis; Giovanna Pomilio; Alex Agrotis; Xiaoming Gao; Xiao-Jun Du; David Curtis; Alexander Bobik
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Fibroblast growth factor signaling in the vasculature.

Authors:  Xuehui Yang; Lucy Liaw; Igor Prudovsky; Peter C Brooks; Calvin Vary; Leif Oxburgh; Robert Friesel
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

3.  Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.

Authors:  Milica Bozic; Angels Betriu; Marcelino Bermudez-Lopez; Alberto Ortiz; Elvira Fernandez; Jose M Valdivielso
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

4.  Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.

Authors:  Mohamed Izikki; Christophe Guignabert; Elie Fadel; Marc Humbert; Ly Tu; Patricia Zadigue; Philippe Dartevelle; Gerald Simonneau; Serge Adnot; Bernard Maitre; Bernadette Raffestin; Saadia Eddahibi
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

5.  Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis.

Authors:  Athanasios Didangelos; Ursula Mayr; Claudia Monaco; Manuel Mayr
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

6.  Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-κB pathway.

Authors:  Fragiska Sigala; Paraskevi Savvari; Michalis Liontos; Panagiotis Sigalas; Ioannis S Pateras; Alexandros Papalampros; Efthimia K Basdra; Evangelos Kolettas; Athanasios G Papavassiliou; Vassilis G Gorgoulis
Journal:  J Cell Mol Med       Date:  2010-09       Impact factor: 5.310

7.  Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention.

Authors:  Mark Slevin; Jerzy Krupinski; Lina Badimon
Journal:  J Angiogenes Res       Date:  2009-09-21

8.  The impact of polyphenols on chondrocyte growth and survival: a preliminary report.

Authors:  Salvador Fernández-Arroyo; Fernando Huete-Toral; María Jesús Pérez de Lara; María de la Luz Cádiz-Gurrea; Laurence Legeai-Mallet; Vicente Micol; Antonio Segura-Carretero; Jorge Joven; Jesús Pintor
Journal:  Food Nutr Res       Date:  2015-10-05       Impact factor: 3.894

9.  A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Frédérique Dol-Gleizes; Nathalie Delesque-Touchard; Anne-Marie Marès; Anne-Laure Nestor; Paul Schaeffer; Françoise Bono
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

10.  Smooth muscle FGF/TGFβ cross talk regulates atherosclerosis progression.

Authors:  Pei-Yu Chen; Lingfeng Qin; Guangxin Li; George Tellides; Michael Simons
Journal:  EMBO Mol Med       Date:  2016-07-01       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.